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Abstract
Malaria is an infectious disease caused by protozoa of the genus Plasmodium, transmitted by the bite of female 
mosquitoes Anopheles. Malaria can infect various populations including pregnant women. The incidence of 
malaria in pregnancy is quite high especially in tropical - endemic regions such as Indonesia, Papua New Guinea, 
Nigeria, West Africa and Sudan.  It happens because there is no enhanced control activities such as two prevention 
approaches advocated by the WHO, as well prevention intermittently with sulfadoxine- pyrimethamine (SP) 
and the treatment of malaria during pregnancy. There are several factors that influence the high prevalence of 
malaria such as mosquito vectors, malaria parasites, human hosts and environment. As a result of the presence 
of malarial parasites in the placenta appear serious adverse outcomes to the mother, fetus and newborn. Malaria 
can be diagnosed with microscopy, rapid diagnostic test (RDT), and polymerase chain reaction (PCR).The first-
line treatments recommended by the WHO in the second and third trimester of pregnancy are artemisinin-based 
combination treatments (ACT).
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Malaria dalam Kehamilan: Telaah Holistik, Pendekatan Laboratorum, Tata Laksana  
dan Luarannya  
Abstrak
Penyakit malaria merupakan infeksi yang disebabkan oleh genus Plasmodium, yang ditularkan melalui gigitan 
nyamuk Anopheles betina. Malaria dapat menginfeksi berbagai populasi termasuk perempuan hamil. Insidens 
malaria dalam kehamilan cukup tinggi terutama di wilayah tropis - endemik seperti Indonesia,  Papua Nugini, Nigeria, 
Afrika Barat, dan Sudan. Hal itu terjadi karena ketiadaan penanggulangan/pencegahan seperti yang dianjurkan 
WHO yaitu pemberian sulfadoxine- pyrimethamine (SP) intermiten dan pengobatan malaria dalam kehamilan. Ada 
banyak faktor yang berperan terhadap kejadian malaria yakni nyamuk sebagai vektor, parasit malaria, manusia 
sebagai pejamu dan lingkungan yang juga berperan terhadap kejadian malaria dalam kehamilan. Malaria dalam 
kehamilan berakibat  serius trehadap ibu, janin dan neonatus. Diagnosis dapat ditegakkan  secara mikroskopi, rapid 
diagnostic test (RDT), dan  polymerase chain reaction (PCR). Pengobatan lini pertama yang direkomendasikan oleh 
WHO pada trimester ke dua dan ketiga kehamilan adalah kombinasi artemisinin  (artemisinin-based combination 
treatments - ACT).
Kata kunci: Malaria, kehamilan, pemeriksaan laboratorium, tatalaksana, luaran 
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findings, management and adverse outcomes 
of malaria in pregnancy. The data taken were 
from the year 2014 to 2017 research articles.
Laboratory Findings
The crucial issue in the management of 
malaria is consideration of the possibility 
of this diagnosis. Malaria should be 
suspected in anyone with a fever or a 
history of fever who has returned from or 
previously visited a malaria endemic area. 
There are no specific symptoms of malaria: 
most patients complain of fever, headache 
and general malaise, gastrointestinal 
disturbances, jaundice.  Malaria infection 
during pregnancy is often asymptomatic.16 
The effects of malaria infection in the first 
trimester are largely unknown.17 Because of 
the low parasitemia found in all age groups 
pregnant women may be the reason why 
they do not show malaria symptoms even 
though they are infected. This suggests 
that pregnant women can become carriers 
of malarial parasites without showing any 
symptoms of infection.18 Malarial parasites 
in pregnancy can be found with microscopy, 
rapid diagnostic test (RDT), and polymerase 
chain reaction (PCR). 
Microscopy examination was made 
using thick and thin smears on the same 
slide and stained with 5 % Giemsa for 30 
minutes.19 A smear was declared negative 
if examination of 100 high power fields did 
not reveal asexual parasites or gametocytes. 
For positive smears, parasite density was 
calculated by counting the number of 
asexual parasites per 200 leukocytes (or per 
500, if the count is <10 asexual parasites/200 
leukocytes), assuming a leukocyte count of 
8,000/μl. When a thick smear was positive, 
the corresponding thin blood smear was read 
to determine the parasite species.20
Malaria rapid diagnostic tests (RDTs) 
assist in the diagnosis of malaria by detecting 
evidence of malaria parasites in human blood. 
Introduction
Malaria is an infection caused by 
protozoa of the genus Plasmodium. The 
species of plasmodium include Plasmodium 
falciparum, Plasmodium vivax, Plasmodium 
ovale and Plasmodium malariae.1According 
to World Health Organization (WHO), most 
of the cases in 2016 were in the African 
(90%), followed by South-East Asia (7%) 
and Eastern Mediterranean (2%).2 Malaria is 
also a cause of mortality and morbidity in 
pregnant women globally.1,3 It is estimated 
125 million women each year are at risk of 
malaria in pregnancy.4-5 The incidence of 
malaria in pregnancy is still high, especially 
in endemic tropical countries such as 
Indonesia  (Papua 10%, Nusa Tenggara 
Timur 5%)6, Papua New Guinea 18,5%, 
Nigeria (Igbo-Eze North 50.7%)7, and West 
Africa 40.2%8 , and Sudan (Blue nile state 
58.9%)9. No enhanced control activities 
as recommended by the WHO, as well 
prevention intermittently with sulfadoxine-
pyrimethamine (SP) and the treatment 
of malaria during pregnancy, it can be a 
potential cause the prevalence remain high.9
Malaria infections could occur in blood 
of mother  or in the placenta.The presence 
of infected erythrocytes or malaria pigment 
(haemozoin) in the placenta intervillous 
referred to as placental malaria. The 
occurrence of placental malaria is influenced 
by many factors such as primipara, multipara, 
live in rural areas, young age ≤ 23.2 year, 
did not undergo the ante natal care (ANC), 
do not use the nets when sleeping, and the 
absence of clinical symptoms malaria.10-12
As a result of the presence of malarial 
parasites in the placenta serious adverse 
outcomes occurs to the mother, fetus and 
newborn such as maternal anemia, low birth 
weight (LBW) baby, intrauterine growth 
restriction, preterm birth (PTB), miscarriage, 
stillbirth, and congenital malaria.6,7,13-15This 
article will discuss about the laboratory 
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for detecting parasites. Whether applied 
to peripheral blood or placental blood 
samples, PCR methods yield positivity rates 
20% or more above those of blood smears 
microscopy. Infections identified by PCR, 
or RDT when microscopy fails to detect 
parasites on blood smears are defined as 
submicroscopic infections. PCR methods 
have been applied to detect submicroscopic 
pregnancy malaria. Although these tools 
are more sensitive for parasite detection 
compared with microscopy, the test format 
and the time to obtain results are not suitable 
for use in a primary care setting.22
 
Management
Therapy
According to the WHO, seven days of 
quinine (10 mg) plus clindamycin (5 mg) 
twice a day is the preferred regimen to treat 
malaria in the first trimester of pregnancy.25 If 
clindamycin is unavailable or unaffordable, 
quinine monotherapy should be given.26 
Although this regimen thought to be safe 
during pregnancy, we should be aware of the 
side effects. Clindamycin does pass through 
the placenta and may be accumulated in the 
fetal liver.27 The use of quinine is limited 
by its disadvantages, including a long 
treatment course and an increased risk of 
hypoglycaemia.28
The first-line treatments now 
recommended by the WHO for malaria in the 
second and third trimester of pregnancy are 
artemisinin-based combination treatments 
(ACT); these are combinations of fast acting 
artemisinin-based compounds that combined 
with a drug from a different class. Artemisinin 
derivatives include dihydroartemisinin, 
artesunate and artemether.29 They are 
eliminated rapidly and well tolerated; none 
of the studies reported serious adverse 
event attributed to the use of artemisinin.30 
Four ACTs are currently recommended: 
The test principle underlying malaria RDTs 
is the detection of parasite antigens, most 
commonly histidine-rich protein 2 (HRP2), 
parasite lactate dehydrogenase (pLDH), 
and/or parasite aldolase through lateral flow 
immunochromatography. Whereas HRP2 is 
specific to Plasmodium falciparum, pLDH 
and parasite aldolase are common to all 
Plasmodium species.21
RDT-HRP2 tests have a higher sensitivity 
compared with RDT-pLDH.22 Based on this 
study, the HRP2 assay showed superior 
sensitivity but inferior specificity compared 
with the pLDH assay. The difference in 
sensitivity between the tests was due mostly 
to better detection with HRP2 at low parasite 
densities. Non-falciparum infections 
contributed to false negative results for both 
RDTs. In particular, in two-thirds of cases in 
which the HRP2 test was negative although 
microscopy detected parasites, the infection 
was caused by non-falciparum species. The 
higher specificity and positive predictive 
value of the pLDH assay was due to the 
fact that pLDH antigenemia closely mirrors 
parasitemia, while HRP2 commonly persists 
in the bloodstream weeks after successful 
treatment of malaria.23
When RDT-HRP2 performed on 
peripheral blood samples for pregnancy 
malaria diagnoses, the sensitivity was more 
than 90% when it compared with peripheral 
blood smears, and 80–95% when it compared 
with placental BSwith specificity between 
61%- 94%. The sensitivity of RDT-HRP2 
using peripheral blood samples was much 
lower when compared with PCR detection 
of parasite nucleic acids in peripheral or 
placental blood.22
Other alternatives for malaria diagnosis 
are DNA/RNA-based detection techniques, 
of which the PCR is the most widely used.24 
PCR methods to detect malaria infection 
were described more than two decades ago, 
and generally more sensitive for detecting 
parasite DNA than thick blood smears 
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lumefantrine per tablet as a 6-dose regimen 
given twice a day for 3 days. The first two 
doses should, ideally, be given 8 hours 
apart.40 It is tolerated very well in the majority 
of cases, but it has the highest grade of 
reinfection because lumefantrine possesses 
short effect that it can be eliminated rapidly.41
Prevention
The prevention of malaria is important 
to reduce adverse outcomes of malaria in 
pregnancy. Centers for Disease Control and 
Prevention (CDC) recommends pregnant 
women who do travel to malaria countries 
to: I) begin a prophylactic antimalarial 
medication such as mefloquine (228 mg) 
or chloroquine (310 mg) before travelling 
begin i.e. two weeks before travel, during 
travelling once a week, on the same day 
of the week and continue post-travel for 4 
weeks,II) 42 wear long-sleeved shirts and long 
pants to prevent mosquito bites, III) remain 
outdoors during peak time, IV) use insect 
repellent with N,N-Diethyl-m-toluamide 
(DEET) or Picaridin, and V) sleep in a well-
screened or air-conditioned room or under 
a mosquito net treated with permethrin.43 
While the inhabitants of endemic areas, 
WHO recommends interventions such 
as intermittent preventive treatment in 
pregnancy (IPTp) and insecticides-treated 
nets (ITNs) to prevent and control malaria 
during pregnancy.44
Intermittent preventive treatment 
in pregnancy is the administration of 
antimalarial medications at predefined 
intervals with the intent to protect a pregnant 
woman against malaria.45 It is advised not 
to be given to pregnant women in the first 
trimester because they are teratogenic 
and may cause fetal death.46 Intermittent 
preventive treatment in pregnancy 
administration of SP, sulphadoxine (500 mg) 
and pyrimethamine (25 mg) starting as early 
as possible in the second trimester until the 
artesunate–mefloquine, dihydroartemisinin-
piperaquine, artesunate–amodiaquine, and 
artemether–lumefantrine.31 The benefits of 
ACTs are their high efficacy, fast action, 
and the reduced likelihood of resistance 
developing.32
The combination of artesunate-
mefloquine is currently one of the most 
effective treatments against malaria in 
pregnancy.33 Typical dosage are 100 mg 
artesunate and 220 mg mefloquine every 
8 hours for 3 days.34 Mefloquine has many 
characteristics such as long half-life, single 
dose administration, a well-characterized 
pharmacokinetic profile in pregnant women, 
and infrequent mefloquine resistance. It 
often gives rise to side effects such as 
asthenia, loss of appetite, dizziness, nausea, 
and vomiting.33,35
New infections can be prevented by long-
acting artemisin such as dihydroartemisin-
piperaquine especially for areas with high 
malaria transmission.36 The fixed dose 
combination formulated in tablets containing 
dihydroartemisinin (40 mg) and piperaquine 
(320 mg) is commercially available in many 
countries in Asia, and also more recently in 
Africa. The fixed combination given once 
daily for 3 days was effective and well 
tolerated. The most common adverse effects 
are gastrointestinal (nausea, vomiting, 
abdominal pain, and diarrhea), but they are 
usually mild and self limiting.37
Artesunate-amodiaquine has the lowest 
side effects on the frequency of pulse 
and blood tension.38 Some studies have 
shown that amodiaquine or combinations 
of amodiaquine with artesunate were 
better at clearing parasitaemia compared 
with chloroquine given alone. The total 
recommended treatment is 50 mg of 
artesunate and 153 mg of amodiaquine once 
a day for 3 days.39
Artemether-lumefantrine is a fixed-dose 
antimalarial drug combination in pregnancy 
containing 40 mg artemether and 240 mg 
45
variant surface antigens VAR2CSA. This 
protective antibody responses develop 
during subsequent pregnancies, providing 
protection against placental malaria. Live 
in rural area increase heterogeneous malaria 
transmission in Papua New Guinean.11 Other 
data showed higher risk of placental malaria 
in women who experienced 0-1 episodes 
of malaria symptoms and <50% of the 
samples LAMP +; and women who have ≥ 
2 episodes of malaria symptoms or ≥ 50% of 
the samples LAMP + compared to pregnant 
women without exposure to malaria.12
Complication of malaria in pregnancy 
include anemia, low birth weight, IUGR, 
premature birth, abortus, stillbirth, and 
congenital malaria. Infection in first or 
second trimester raise the risk of LBW, 
wherein acute infection of malaria is 
associated with LBW, with an average 
birth weight 199 gram lower. Acute malaria 
infection with high parasitemia is associated 
with premature birth. Chronic infection 
also associated with premature birth, while 
chronic placental malaria infection with 
chronic massive intervillositis is associated 
with anemia and LBW in pregnancy, 
specifically moderate anemia (7.0-8.9 g/dL) 
and severe anemia (<7.0 g/dL). Pregnant 
women with malaria are 33% more likely 
to develop anemia. Low birth weight is also 
associated with peripheral malaria infection 
during labor. 9,11,43
Infection of P. falciparum in early 
pregnancy can cause  intra uterine growth 
restriction (IUGR)  between 212-253 days 
of gestational age, and the gestational age 
becomes shorter. Birth weight and weight 
of the placenta also found reduced. Small 
placental volumes in early pregnancy may 
be used as IUGR predictor at birth. Small 
placental size is associated with disorder 
of trophoblast invasive, late complication, 
and premature birth due to exposure 
to the VAR2CSA protein. The process 
underlining VAR2CSA cause IUGR is not 
time of delivery, with doses given at least 1 
month apart, so that women receive at least 
three doses of SP during pregnancy.47
The usage of treated nets offer a form 
of personal protection and have repeatedly 
been shown to reduce severe diseases and 
death due to malaria for both the pregnant 
women and children in endemic regions.48 
The insecticides used for treating the nets 
kill mosquitoes and other insects. This 
insecticide also has repellent properties 
that reduce the number of mosquitoes that 
enter the house and attempt to feed thereby 
offering protection not only for the person 
under the net but also for those in the same 
room with the net owner.49 In addition, other 
similar protection such as indoor insecticide 
residual sprays (IRS) and mosquito coils 
(MC) can also be used.50
Several studies have also mentioned 
some alternatives that can prevent malaria 
in pregnancy such as the consumption 
of azithromycin-chloroquine (250 mg 
azithromycin, 155 mg chloroquine) in 
combination doses, or supplementation 
with 25 mg zinc and 2500 IU vitamin A 
everyday.51-53 However, there has not been 
much research to discuss this.
Outcomes
Malaria infections during pregnancy 
are often asymptomatic.16 The effects of 
malaria infection in the first trimester are 
mostly unknown.17 Low parasitemia found 
in all pregnant women age group may be the 
reason why malaria infection did not show 
any symptoms. This suggests that pregnant 
women can become carriers of malarial 
parasites without showing any symptoms of 
infection.18 
Women primigravida uniquely 
vulnerable because they do not have 
a specific malaria immunity during 
pregnancy in the form of antibodies and 
memory B cells against a specific parasite 
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caused by the transmission of the parasite 
through the placental before or during the 
labor. In Burundi, prevalence of congenital 
malaria shows 0% even though the survey 
was carried in meso-endemic area while 
in the wet, high transmission season. It is 
assumed that during the high transmission 
season, mothers acquired a high immunity 
level and their malaria specific antibody rise 
when the mothers exposed to the infection. 
None of the newborns born from microscopy 
or RDT positive mothers found to be qPCR-
positive might can confirm that placenta play 
an effective role as a barrier. Two newborns 
born from mothers with high parasitemia 
found to be HRP-2 RDT positive, but 
negative with qPCR, suggest that the HRP-2 
antigen can pass through the placenta, while 
the DNA isn’t transmitted.55
Compared to Burundi, in Maumere, 
Indonesia, the prevalence of congenital 
malaria in selected subgroup of newborns 
with an increased risk of congenital 
malaria was 42,4%, while the prevalence 
in all newborns was 14,7%. The congenital 
infection of the parasite can occur at 
different time, either it is in utero or during 
labor. The mechanism might be done by 
direct penetration through the chorionic villi 
or might be through premature separation 
of the placenta. The infected infants are at 
4,7 times higher risk to develop anemia. 
Congenital malaria mostly found in first or 
second child, similar to placental malaria.56
Infants born to mothers that has been 
exposed to malarial infection more than 
once, or experienced placental malaria 
before, have higher risk of impaired growth 
in the first year of life. Infants born to 
mothers infected with malaria in their first 
year of life may experience at least one 
episode of malaria (5%), acute respiratory 
infection (51%), or diarrhea (22%). The 
risk of malaria infection in infants increased 
three-folds in infants born to mothers with 
peripheral malaria infections, dan increase 
fully understood. Plasmodium falciparum 
divide itself in erythrocyte, makes the 
infected erythrocytes are more prone to 
be discharged into the spleen. To prevent 
it, the parasite express P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) 
in the surface of infected cells. PfEMP1 is 
a multiprotein and each of the parasite’s 
genome encoded around 60 different variant 
of protein, which one of it is VAR2CSA. 
This protein binds to most of tumor cells, 
the bound cells show decreased migration, 
invasion, and growth. VAR2CSA also binds 
infected erythrocyte to syncytiotrophoblast 
expressed glycosaminoglycan and present 
in the intervillous section. The infected 
erythrocyte triggers the inflammation 
response that negatively affected the 
fetal growth. VAR2CSA also may affect 
trophoblast and cause permanent damage to 
proper uteroplacental circulation.13
Plasmodium falciparum detected during 
labor in peripheral blood flow and in the 
placental blood flow increase the risk of 
stillbirth, meanwhile Plasmodium vivax 
increase the risk of stillbirth if detected 
during labor but not when detected and 
treated during pregnancy. Association 
between P. falciparum infection during 
pregnancy and stillbirth is two times higher 
in low-medium endemic area compared to 
high-endemic area. Increased CLCX9 in 
peripheral blood flow during pregnancy 
linked with increased risk of born premature 
and abortus. Increased exosome or change 
of microparticles composition activated 
peripheral mononuclear cells has been 
speculated to cause proinflammation 
immune response which associated with born 
premature and abortus. Increased of IL-1β di 
placental blood circulation also associated 
with miscariage and born premature.4,54
Congenital malaria defined as presence 
of the malaria parasites in asexual form 
either in placental blood flow or in peripheral 
blood flow during the first week of life, 
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artemisinin derivatives and quinine treatments 
and the risk of adverse pregnancy outcomes in 
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16. Cohee LM, Kalilani-Phiri L, Boudova S, Joshi S, 
Mukadam R, Seydel KB, et al. Submicroscopic 
malaria infection during pregnancy and the impact 
of intermittent preventive treatment. Malaria J. 
2014;13(274):1-9
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pregnant women prioritized for bed nets? An 
assessment using survey data from 10 African 
countries. Global Health: Science and Practice. 
2014;2(2):165-71.
18. Abe AF, Olusi TA. Seroprevalence of malaria 
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attending two tertiary health facilities in 
Akure Ondo State Nigeria. J Bacteriol Pasitol. 
2014;5(4):1-6
19. Ahmed R, Levy EI, Maratina SS, de Jong JJ, Asih 
more than ten-folds in infants born to mother 
with placental malaria.57
Conclusion
Malaria in pregnancy is common in 
everyday life, especially in endemic areas. 
Therefore, with prevention as early as 
possible, the definitive diagnosis and the 
best therapy should make pregnant women 
free from adverse outcomes such as maternal 
anemia, miscarriage, intrauterine growth 
restriction, low birth weight, preterm birth, 
stillbirth, and congenital malaria.
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